The export to the Translational Psychedelic Research Program at UCSF represents an important step in advancing clinical research on natural psilocybin Vancouver, British Columbia, August 26, 2021 – Filament Health Corp. (NEO:FH) (“Filament” or the “Company”), a leading exclusively-natural psychedelic drug development company, today announced that it has completed a shipment of Good Manufacturing…


Previous articleScientists Isolate Two New Compounds from Toad Venom
Next articlePTSF74 – A Response: Decriminalize Nature, SB-519, and MAPS